Comparative Pharmacology
Head-to-head clinical analysis: SERAX versus TEMAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SERAX versus TEMAZ.
SERAX vs TEMAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SERAX (oxazepam) is a benzodiazepine that modulates GABA-A receptors, enhancing the inhibitory effect of GABA, leading to anxiolytic, sedative, and anticonvulsant effects.
Temazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to anxiolytic, sedative, and hypnotic effects.
Oral: 5-10 mg twice daily; maximum 20 mg/day. Intravenous: 2-5 mg slow IV push, may repeat after 2 hours.
Temazepam 15-30 mg orally at bedtime, up to 60 mg if needed.
None Documented
None Documented
Terminal elimination half-life is 8-15 hours (mean 12 hours) in adults; prolonged in renal impairment.
Clinical Note
moderateTemazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Temazepam."
Clinical Note
moderateTemazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol."
Clinical Note
moderateTemazepam + Sulfisoxazole
Terminal elimination half-life: 1.5–2 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 4–6 hours, requiring dose adjustment.
Primarily renal (urinary) as unchanged drug (60-80%) and metabolites (20-40%); less than 5% fecal elimination.
Renal: ~80% as unchanged drug and metabolites; biliary/fecal: ~20%.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Sulfisoxazole can be decreased when combined with Temazepam."